Restafen Plus

Quick links to important sections

Restafen Plus

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Restafen Plus

Property Description
Active ingredient Etofenamate, Nicotinic Acid derivative
Form Cream or Gel
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID) and Topical Vasodilator
Common use Localized relief of musculoskeletal pain and inflammation
Origin Synthetic

What Type of Medicine is Restafen Plus?

Restafen Plus is a specialized synthetic fixed-dose combination product intended for topical administration as a cream or gel, classified broadly as an Anti-rheumatic drug and Analgesic. The formulation features two essential active ingredients: the Non-Steroidal Anti-Inflammatory Drug (NSAID), Etofenamate, and a Nicotinic Acid derivative that acts as a localized blood flow enhancer. This particular combination is recognized for its application in addressing conditions like back pain and localized joint pain. Etofenamate itself is chemically a flufenamic acid derivative, and its classification falls under topical anti-inflammatory preparations.

The Dual-Action Composition: Etofenamate and Nicotinic Acid

The composition strategically pairs the NSAID, Etofenamate, with the Nicotinic Acid derivative, a Topical Vasodilator component. Etofenamate functions by achieving the core anti-inflammatory effect via the Inhibition of Prostaglandin synthesis, a mechanism for pain mitigation. The role of the Nicotinic Acid derivative is to stimulate local hyperemia and increase microcirculation, a strategy designed to enhance the transcutaneous penetration of the NSAID. The overall design emphasizes localized treatment, ensuring the analgesic effect is delivered to the source of **musculo-skeletal system inflammatory disorders.

How Does This Topical Combination Differ from Standard NSAIDs?

The inclusion of the Topical Vasodilator is the key differentiating factor, intended to optimize the delivery and focus of the medication. Unlike standard NSAID gels or creams, Restafen Plus utilizes this dual mechanism of action to achieve local concentrations of the anti-inflammatory agent. By improving drug access through temporary vasodilation, the combination maximizes the exposure of the painful area to the analgesic effect of Etofenamate, for targeted relief where deeper tissue penetration is desired. This formulation is exclusively designed for topical administration.

Regulatory References

  1. NSAIDs Mechanism of Action (NIH)

What side effects are possible with Restafen Plus?

Possible side effects and safety information

The safety profile for this topical preparation is primarily defined by the non-steroidal anti-inflammatory drug (NSAID) component, Etofenamate, and focuses heavily on reactions at the site of application. Regulatory documents organize documented adverse reactions by frequency and physiological system, providing a framework for understanding potential risks.

Frequency-Classified Adverse Reactions

The most commonly documented adverse events are those related to the Skin and Subcutaneous Tissue Disorders.

Classification Examples of Reactions System-Organ Class
Common Localized erythema (redness), pruritus (itching), local irritation. Skin Disorders
Rare Contact dermatitis, photosensitive dermatitis, allergic skin reactions. Skin Disorders
Very Rare/Not Known Anaphylactic reaction, severe cutaneous adverse reactions (SCARs). Immune System Disorders

Serious Adverse Reactions and Safety Constraints

Although systemic absorption is generally low, the regulatory documents recognize the potential for Very Rare but serious systemic adverse reactions associated with the NSAID class, such as anaphylactic events, bronchospasm, and severe skin syndromes (e.g., Stevens-Johnson Syndrome). These serious reactions are documented as part of the overall safety profile.

Official labeling includes specific safety considerations for patient populations and use contexts. The product is contraindicated during the third trimester of pregnancy and in patients with known hypersensitivity to other NSAIDs or aspirin. Furthermore, it should not be applied to open wounds, damaged skin, or mucous membranes. The potential for systemic effects increases when the preparation is used on large skin areas or for prolonged periods.

Overdose and Emergency Response

Restafen Plus is a topical medication, and official regulatory documents state that overdosage is not considered a practical possibility through the intended route of administration. The primary risk requiring emergency action is related to accidental oral ingestion, particularly in young children, which can lead to systemic exposure to Etofenamate.

If significant systemic overdose occurs, manifestations are consistent with acute Non-Steroidal Anti-Inflammatory Drug (NSAID) toxicity. Initial documented signs may include gastrointestinal disturbances such as epigastric pain, nausea, vomiting, and diarrhoea. More severe outcomes officially described include Central Nervous System effects like seizures and coma, as well as serious organ damage such as acute renal failure and shock.

Immediate medical attention is required for any suspected oral ingestion or if severe symptoms, such as loss of consciousness or trouble breathing, are observed. Regulatory guidance mandates that a poison control center or emergency services be contacted in these situations. Management is symptomatic and supportive, as no specific antidote is known. This includes clinical monitoring, ensuring adequate hydration, and checking renal function as part of the procedural steps described for severe NSAID toxicity.

Therapeutic Uses of Restafen Plus

Quick Facts

  • Support for Symptoms: May offer relief from discomfort related to soft tissue injuries and joint issues.
  • Targeted Use: Is utilized to address localized pain and inflammation.
  • Therapeutic Role: Helps manage symptoms in conditions like tendinitis and certain rheumatic problems.

Restafen Plus is a prescription-only topical medication intended for the local management of musculoskeletal symptoms. Its main purpose is to support individuals experiencing discomfort associated with soft tissue rheumatism, such as tenosynovitis (inflammation of a tendon sheath) and bursitis (inflammation of the bursa). The topical application is designed to help address localized inflammation and pain in these areas.

The medication is also utilized as a supportive measure in the management of post-traumatic conditions, including strains, sprains, and contusions (bruises), and in addressing pain related to superficial thrombophlebitis. It is part of the therapeutic options considered by healthcare professionals to assist in the improvement of mobility and overall comfort in affected joints and surrounding tissues. Patients should consult their doctor for personalized medical guidance and to understand the established therapeutic domains for this product.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Restafen Plus

The use of Restafen Plus is defined by specific population eligibility rules established by regulatory authorities.

Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated for use in patients with a known hypersensitivity to Etofenamate, flufenamic acid, aspirin, or any other Non-Steroidal Anti-Inflammatory Drug (NSAID). Application is prohibited on broken skin, open wounds, ulcers, or eczema. The product must also be avoided on the eyes and mucous membranes. Use is also contraindicated during the third trimester of pregnancy.

Restricted and Not Recommended Populations

Population Group Regulatory Status Basis for Restriction
Children and Infants Not Recommended Safety and efficacy have not been formally established.
Pregnancy (General) Not Recommended Safety to the fetus is unestablished.
Lactation Not Recommended Safety to the suckling infant is unestablished.

Other Eligibility Rules

Restafen Plus is indicated for Adults. The product is contraindicated when applied under occlusive dressings. While no specific dosage change is indicated for patients with renal or hepatic impairment, use in these populations should still align with clinical guidance for topical NSAIDs.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Restafen Plus is a topical combination product containing Etofenamate (an NSAID) and a Nicotinic Acid derivative. Due to its cutaneous route of administration, the product's official interaction profile is primarily defined by local administration restrictions, as systemic absorption is low.

Official Interaction Restrictions and Classifications

The most significant documented interaction constraint is an administration-timing rule classified as a contraindication. Co-administration is formally prohibited when the product is applied simultaneously to the same skin site as any other topical preparation. This restriction exists to prevent local interactions and ensure consistent percutaneous absorption of the active substances.

Regarding systemic interactions, the official regulatory documents for the topical formulation state that no systemic drug-drug interactions are known. This absence of documented interactions covers common metabolic and transporter pathways (e.g., CYP enzymes, P-gp) and pharmacodynamic effects.

  • Population-Specific Note: The regulatory assessment specifically addresses the risk of interaction with anti-coagulant therapy. Clinical studies found no indication of a need to alter the recommended topical dosage in patients undergoing anti-coagulant treatment, reflecting the negligible risk of a clinically significant systemic interaction at the therapeutic dose.

  • Food/Substance Interactions: No specific interactions with food, alcohol, or herbal products are documented in the official regulatory texts for the topical product.

Mechanism of Action

Dual Mechanism: Inhibition of Inflammatory Enzymes

This mechanism employs a core action targeting the Cyclooxygenase (COX) enzymes in peripheral tissues. The Etofenamate component acts as a non-selective inhibitor, preventing the production of key mediators like Prostaglandins. This interruption of the Arachidonic Acid Cascade is a foundational mechanism that modulates the local inflammatory cascade and decreases the chemical sensitization of peripheral nociceptors.


Synergy Through Local Microcirculation Enhancement

Simultaneously, a synergistic mechanism is provided by the Nicotinic Acid derivative, which directly modulates local vascular tone. This component acts on specific Prostanoid receptors on blood vessel walls, causing immediate vasodilation and a resultant increase in local microcirculation (hyperemia). This physiological change strategically enhances the transcutaneous flux and effective local concentration of the NSAID component, optimizing the concentration-dependent kinetics of the enzyme inhibition at the peripheral site of action.


Physiological Effect: Targeted Peripheral Response

The combined mechanism leads to a highly targeted, strictly peripheral physiological response. The drug limits the impact of key inflammatory mediators while simultaneously ensuring high local delivery of the inhibitor. The overall effect is the modulation of localized inflammatory signaling pathways, contributing to an adjusted physiological response within the targeted tissue.

Dosage and Administration Information

The principles for using Restafen Plus relate to its formulation as a topical preparation.

Administration and Dosage

The route of administration is exclusively topical, meaning the product—available as a cream or gel—is applied directly to the skin surface. The dosing amount is determined by the size of the area requiring treatment.

For a single application, the standard amount is measured as a continuous strip of product, typically 5 cm to 10 cm in length. The preparation should be rubbed gently into the skin until absorbed. This process may be repeated up to four times daily to maintain the necessary local concentration of the active ingredients.

Usage Constraint Label Guidance
Dosing Frequency Up to four times daily (divided use)
Course Duration Use should be reviewed after 14 days for acute soft tissue injury or 21 to 28 days for longer-term symptoms
Older Adults No specific dose adjustment from the standard adult regimen is required
Pediatric Use Use in children and infants is not recommended

Standard application for this product class involves applying it to the affected area. For individuals with impaired kidney or liver function, no change to the recommended topical dosage is required. These parameters define the standardized use of the medicine.

Recent Clinical Evidence

Restafen Plus: Recent Clinical Evidence

This section summarizes the findings from clinical research that has evaluated the actions and profile of Restafen Plus.


Studies Evaluating the Drug's Effects

Research has explored whether the drug's action, which may involve modulating serotonin receptors in the brain, is associated with changes in mood and symptoms of anxiety. Clinical trials have also examined whether there is an effect on patient-reported quality of life.

Research on the Speed of Effect

A large-scale, randomized controlled trial (RCT) evaluated changes in anxiety scores during the initial period of treatment. The results of these studies were evaluated relative to placebo and, in some cases, alongside other existing treatments. Research recorded the percentage of study participants who discontinued treatment.


Research on Prolonged Administration

Long-term safety studies have been conducted to evaluate the effects of prolonged administration over extended periods. Research has characterized the observations of prolonged administration, and studies recorded common side effects, which were often described as mild.

Research has tracked how the incidence of these effects may change over the initial period of administration. Furthermore, research has also explored the use of this drug in populations with persistent anxiety.

Frequently Asked Questions (FAQ)

Common questions about Restafen Plus (FAQ)

Q: Can Restafen Plus be taken by someone who has high blood pressure?

The official product information for the topical formulation of Restafen Plus indicates that it has low systemic absorption, meaning very little of the medicine enters the bloodstream. Because of this, high blood pressure is not listed as an absolute contraindication in the official documents. However, since the product contains a non-steroidal anti-inflammatory drug (NSAID), its use is a safety consideration associated with the general NSAID drug class, which may require clinical consideration.


Q: Are there known interactions between Restafen Plus and common herbal supplements?

According to the regulatory documents for the topical gel or cream, no systemic drug-drug interactions are known. This means that no specific interactions are documented between this topical product and common herbal supplements, food, or alcohol.


Q: Is Restafen Plus suitable for someone who has allergies to other medicines?

Official safety information describes that the product is formally contraindicated if you have a known hypersensitivity or allergy to any of its ingredients. This contraindication also extends to known allergies to other non-steroidal anti-inflammatory agents (NSAIDs), including aspirin.


Q: Can Restafen Plus be crushed or chewed?

Restafen Plus is a topical preparation, meaning it is formulated as a cream or gel for application directly to the skin. It is not an oral medication. The product is strictly for topical use and must be used according to the defined route of administration on the label.


Q: Is Restafen Plus considered a narcotic or controlled substance?

Restafen Plus contains an NSAID (Etofenamate) and a Nicotinic Acid derivative. The official classifications for these active ingredients categorize the product as an analgesic and anti-rheumatic drug. It is not generally listed as a narcotic or controlled substance.


Q: Does Restafen Plus affect the immune system?

The mechanism of action targets local inflammation in the peripheral tissues, rather than the systemic immune system. However, the documented safety profile for the NSAID class of medicines recognizes the potential for very rare reactions classified under Immune System Disorders, such as anaphylactic reactions and severe allergic skin reactions.


Q: How quickly should I expect to feel the effects of Restafen Plus?

Official product information indicates that the active ingredient, Etofenamate, is readily transported through the skin and concentrated in the inflamed tissue to begin its localized anti-inflammatory and analgesic effects. However, official product information does not specify a timeline for the onset of pain relief.


Q: Is Restafen Plus known to cause fatigue?

Fatigue is not listed in the official frequency-classified adverse reaction sections documented in the product's regulatory safety profile. These sections include common, rare, and very rare side effects.


Q: Do I need a prescription to get Restafen Plus?

The regulatory access status for Etofenamate-containing products, whether Over-The-Counter (OTC) or Prescription-Only, can vary depending on the country's local health authority. While the active ingredient is available OTC in several international markets, the status must be confirmed locally.


Q: Is Restafen Plus the same kind of medicine as Advil or Tylenol?

Restafen Plus contains Etofenamate, which belongs to the same broad drug class, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), as Advil (Ibuprofen). However, Restafen Plus is a topical combination product containing an additional ingredient (Nicotinic Acid derivative) for localized action. It is not in the same drug class as Tylenol (Acetaminophen/Paracetamol).


Q: Is it true that Restafen Plus is used for nerve pain?

Official indications and supporting research for the active ingredient Etofenamate include use in painful conditions of the locomotor system, such as neuralgias (like sciatica) and low back pain.


Q: Can Restafen Plus cause weight gain?

Weight gain is not listed in the official frequency-classified adverse reaction sections (Common, Rare, Very Rare) documented in the product's safety profile.


Q: Is Restafen Plus effective for all types of pain?

It is indicated for the localized relief of musculoskeletal pain and inflammation, such as sprains, strains, or joint pain. Since the medicine is applied topically to a specific area, its use is focused on targeted, non-systemic pain conditions.


Q: Do the official documents mention Restafen Plus being taken 'as needed'?

Official guidance defines the maximum frequency of application, stating that the application may be repeated up to four times daily. While this allows flexibility within the daily limit, the specific terminology 'as needed' is not explicitly used. The application frequency is constrained by the total daily applications defined in the instructions.


Q: Are there studies on Restafen Plus use in teenagers?

The product's official labeling states that it is not recommended for use in children and infants. Regulatory documents typically only contain specific guidance for patient populations where safety and efficacy have been formally established in trials.


Q: Can Restafen Plus affect my ability to drive?

The Summary of Product Characteristics (SmPC), a key regulatory document, states that the product’s Effects on the ability to drive and use machines are considered 'Not applicable.' This is consistent with its topical administration and low systemic absorption.


Q: Is it okay to take Restafen Plus if I'm already taking a multivitamin?

The official regulatory documents state that no systemic drug-drug interactions are known for the topical formulation. Therefore, no systemic interactions are documented with multivitamins or other common supplements.


Q: Why do some people say they feel restless after taking Restafen Plus?

Restlessness is not listed in the official frequency-classified adverse reaction sections (Common, Rare, Very Rare) documented in the product's safety profile.


Q: Can Restafen Plus cause changes in mood or behavior?

Changes in mood or behavior are not listed in the official frequency-classified adverse reaction sections (Common, Rare, Very Rare) documented in the product's safety profile.


Q: Is it safe to take Restafen Plus during the summer heat?

Official storage guidelines require the product to be stored at a temperature not exceeding 25 C and prohibit freezing. This indicates that temperature control is necessary to maintain the product's stability and quality over time.


Q: What does the drug's safety classification mean?

The safety classification, whether prescription or over-the-counter, is assigned by the local regulatory authority. The active ingredient is frequently available as an Over-The-Counter (OTC) medicine in several global markets. This classification means the product is typically available for purchase without a prescription.


Q: Why does Restafen Plus list dizziness as a possible side effect?

Dizziness is not listed in the official frequency-classified adverse reaction sections (Common, Rare, Very Rare) documented in the product's safety profile.


Q: Is it normal to feel a dry mouth while taking Restafen Plus?

Dry mouth is not listed in the official frequency-classified adverse reaction sections (Common, Rare, Very Rare) documented in the product's safety profile.


Q: Can Restafen Plus be used to treat migraines?

The drug is officially indicated for the localized relief of musculoskeletal pain and inflammation and is applied topically to the affected area. This contrasts with systemic treatments typically used for generalized conditions like migraines.

How should Restafen Plus be stored and disposed of?

The storage and disposal of Restafen Plus (Etofenamate/Nicotinic Acid derivative) must strictly adhere to the requirements specified in the official regulatory documentation to ensure product stability and safety.

Official Storage Requirements

Storage Constraint Regulatory Requirement
Temperature Store at a temperature not exceeding 25 C.
Freezing The product must not be frozen.
Shelf-Life Do not use the medicine after the labeled expiry date.

Protection and Disposal

The product must be kept out of the sight and reach of children to prevent accidental misuse. Unused or expired Restafen Plus must not be disposed of via household waste or down the drain, as this can affect the environment. Patients are instructed to return all no-longer-required medicine to a local pharmacy for proper pharmaceutical waste disposal, according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Restafen Plus found in:

A-Z Index: